Skip to main content

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

2
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Prevail Therapeutics
1 program
1
LY3650150Phase 3
Longbio Pharma
Longbio PharmaChina - Shanghai
1 program
1
LP-003 InjectionPhase 23 trials
Active Trials
NCT07816432Not Yet Recruiting12Est. Oct 2027
NCT07785063Not Yet Recruiting80Est. Nov 2029
NCT07313917Not Yet Recruiting150Est. Sep 2027
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Biologic drugsN/A1 trial
Active Trials
NCT06617754Active Not Recruiting3,000Est. Jan 2032
Chia Tai TianQing Pharmaceutical Group
1 program
TQC2731 injectionPHASE_31 trial
Active Trials
NCT07107256Active Not Recruiting246Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
2031
Chia Tai TianQing Pharmaceutical GroupTQC2731 injection
Longbio PharmaLP-003 Injection
Longbio PharmaLP-003 Injection
Longbio PharmaLP-003 Injection
Allergy TherapeuticsBiologic drugs

Clinical Trials (5)

Total enrollment: 3,488 patients across 5 trials

NCT07107256Chia Tai TianQing Pharmaceutical GroupTQC2731 injection

Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps

Start: Sep 2025Est. completion: Sep 2027246 patients
Phase 3Active Not Recruiting
NCT07816432Longbio PharmaLP-003 Injection

A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy

Start: Sep 2026Est. completion: Oct 202712 patients
Phase 2Not Yet Recruiting
NCT07785063Longbio PharmaLP-003 Injection

Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients

Start: Sep 2026Est. completion: Nov 202980 patients
Phase 2Not Yet Recruiting
NCT07313917Longbio PharmaLP-003 Injection

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Start: Jan 2026Est. completion: Sep 2027150 patients
Phase 2Not Yet Recruiting
NCT06617754Allergy TherapeuticsBiologic drugs

International Severe CRSwNP Registry 2024-2028

Start: Mar 2025Est. completion: Jan 20323,000 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.